anifrolumab   Click here for help

GtoPdb Ligand ID: 8258

Synonyms: anifrolumab-fnia | MDX-1333 | MEDI-546 | Saphnelo®
Approved drug Immunopharmacology Ligand
anifrolumab is an approved drug (FDA (2021), EMA (2022))
Compound class: Antibody
Comment: Anifrolumab is a monoclonal antibody targeting IFNAR1 (the receptor for α, β and ω interferons), that was developed by the MedImmune subsidiary of AstraZeneca as a treatment for systemic lupus erythematosus (SLE).
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. [3]. Sequence BLAST using the heavy and light chain variable regions of anifrolumab provides 100% matches to sequences that are claimed in patent US7662381 [3]. The sequence matches identify anifrolumab as clone 11E2 in the patent.
Click here for help
1. Batteux F, Palmer P, Daëron M, Weill B, Lebon P. (1999)
FCgammaRII (CD32)-dependent induction of interferon-alpha by serum from patients with lupus erythematosus.
Eur Cytokine Netw, 10 (4): 509-14. [PMID:10586117]
2. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. (2001)
Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus.
Science, 294 (5546): 1540-3. [PMID:11711679]
3. Cardarelli JM, Witte A, Srinivasan M. (2010)
Interferon alpha receptor I antibodies and their use.
Patent number: US7662381. Assignee: Medarex, Inc.. Priority date: 21/06/2004. Publication date: 16/02/2010.
4. Foulis AK, Farquharson MA, Meager A. (1987)
Immunoreactive alpha-interferon in insulin-secreting beta cells in type 1 diabetes mellitus.
Lancet, 2 (8573): 1423-7. [PMID:2891993]
5. Hooks JJ, Jordan GW, Cupps T, Moutsopoulos HM, Fauci AS, Notkins AL. (1982)
Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis.
Arthritis Rheum, 25 (4): 396-400. [PMID:6176247]
6. Luft T, Luetjens P, Hochrein H, Toy T, Masterman KA, Rizkalla M, Maliszewski C, Shortman K, Cebon J, Maraskovsky E. (2002)
IFN-alpha enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells.
Int Immunol, 14 (4): 367-80. [PMID:11934873]
7. Luft T, Pang KC, Thomas E, Hertzog P, Hart DN, Trapani J, Cebon J. (1998)
Type I IFNs enhance the terminal differentiation of dendritic cells.
J Immunol, 161 (4): 1947-53. [PMID:9712065]
8. Paquette RL, Hsu NC, Kiertscher SM, Park AN, Tran L, Roth MD, Glaspy JA. (1998)
Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells.
J Leukoc Biol, 64 (3): 358-67. [PMID:9738663]
9. Radvanyi LG, Banerjee A, Weir M, Messner H. (1999)
Low levels of interferon-alpha induce CD86 (B7.2) expression and accelerates dendritic cell maturation from human peripheral blood mononuclear cells.
Scand J Immunol, 50 (5): 499-509. [PMID:10564553]
10. Santini SM, Lapenta C, Logozzi M, Parlato S, Spada M, Di Pucchio T, Belardelli F. (2000)
Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice.
J Exp Med, 191 (10): 1777-88. [PMID:10811870]
11. Ytterberg SR, Schnitzer TJ. (1982)
Serum interferon levels in patients with systemic lupus erythematosus.
Arthritis Rheum, 25 (4): 401-6. [PMID:6176248]